Pulike Biological Engineering, Inc.

Shanghai Stock Exchange 603566.SS

Pulike Biological Engineering, Inc. Net Income for the year ending December 31, 2023: USD 24.58 M

Pulike Biological Engineering, Inc. Net Income is USD 24.58 M for the year ending December 31, 2023, a 1.08% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Pulike Biological Engineering, Inc. Net Income for the year ending December 31, 2022 was USD 24.32 M, a -36.71% change year over year.
Pulike Biological Engineering, Inc. Net Income for the year ending December 31, 2021 was USD 38.42 M, a 10.12% change year over year.
Pulike Biological Engineering, Inc. Net Income for the year ending December 31, 2020 was USD 34.89 M, a 122.41% change year over year.
Pulike Biological Engineering, Inc. Net Income for the year ending December 31, 2019 was USD 15.69 M, a -20.44% change year over year.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

Shanghai Stock Exchange: 603566.SS

Pulike Biological Engineering, Inc.

CEO	Mr. Wei Hu
IPO Date	May 18, 2015
Location	China
Headquarters	No.15 Zhenghe Road
Employees	1,679
Sector	Healthcare
Industries Biotechnology Pet Food Pharmaceuticals Vaccines

Description

Pulike Biological Engineering, Inc. engages in the research and development, production, and marketing of veterinary biological products and drugs. It offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. The company is headquartered in Luoyang, China.

Key trends

Past 5 years